| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200806-953OC |
| P698 | PubMed publication ID | 18931333 |
| P50 | author | Kimberley A. Goldsmith | Q57025481 |
| Joanna Pepke-Zaba | Q66126627 | ||
| Robin Condliffe | Q79640755 | ||
| P2093 | author name string | Andrew J Peacock | |
| J Simon R Gibbs | |||
| Paul A Corris | |||
| David G Kiely | |||
| Martin Johnson | |||
| J Gerry Coghlan | |||
| Charlie A Elliot | |||
| Rodney J Hughes | |||
| Chantal Torpy | |||
| Clare Das | |||
| Denise Hodgkins | |||
| Florenc Vrapi | |||
| Julia DeSoyza | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | arterial hypertension | Q41861 |
| connective tissue | Q25615 | ||
| P304 | page(s) | 151-157 | |
| P577 | publication date | 2008-10-17 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era | |
| P478 | volume | 179 |
| Q35096375 | A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis |
| Q64267956 | Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis |
| Q37106203 | Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension |
| Q36272405 | Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension |
| Q87903718 | An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature |
| Q37973014 | An update on the evaluation and management of pulmonary hypertension in scleroderma. |
| Q37206944 | Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients |
| Q36098875 | Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry |
| Q33849207 | Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies |
| Q34987366 | Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study |
| Q35620391 | Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition? |
| Q38871200 | CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features |
| Q34251904 | Cardiac manifestations in systemic sclerosis |
| Q49375001 | Cardiopulmonary Manifestations of Collagen Vascular Diseases |
| Q39322066 | Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners |
| Q41789551 | Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension |
| Q36752821 | Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype |
| Q61894832 | Clinical Assessment of Pulmonary Hypertension |
| Q38218044 | Clinical and laboratory profiles of 136 systemic sclerosis patients with and without echocardiographically detected pulmonary hypertension |
| Q42670331 | Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension |
| Q43941028 | Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus |
| Q47909446 | Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. |
| Q36272410 | Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension |
| Q35029607 | Connective tissue disease-associated pulmonary arterial hypertension. |
| Q44273441 | Connective tissue diseases: To screen or not to screen for PAH in connective tissue diseases? |
| Q38721897 | Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). |
| Q38914965 | Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension |
| Q92894022 | Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension |
| Q38271027 | Early detection of pulmonary arterial hypertension |
| Q37686449 | Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme |
| Q86504980 | Epidemiology of pulmonary arterial hypertension |
| Q39382663 | Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension |
| Q33834751 | Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study |
| Q37763779 | Evidence-based management of rapidly progressing systemic sclerosis |
| Q36066243 | Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review |
| Q36246144 | Exercise training in pulmonary arterial hypertension associated with connective tissue diseases |
| Q35228404 | Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy |
| Q46000874 | Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. |
| Q34410414 | Experience with exercise right heart catheterization in the diagnosis of pulmonary hypertension: a retrospective study. |
| Q64248225 | Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus |
| Q33806102 | From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension |
| Q47771395 | Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure |
| Q88733635 | Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study |
| Q34032884 | Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. |
| Q56977982 | Hypertension artérielle pulmonaire et sclérodermie systémique : les pièges |
| Q48758063 | Implications of Exercise-Induced Pulmonary Arterial Hypertension |
| Q43517026 | Improved survival in limited scleroderma-related pulmonary artery hypertension |
| Q36293847 | In search of markers of treatment failure and poor prognosis in IPAH - the value of mosaic lung attenuation pattern on thin-section CT scans |
| Q64110205 | Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study |
| Q34923343 | Increased Expression of Growth Differentiation Factor-15 in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension |
| Q89147893 | Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension |
| Q58735426 | Inflammation in Right Ventricular Failure: Does It Matter? |
| Q42407453 | Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension |
| Q39061311 | Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity |
| Q41770246 | Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis |
| Q91649600 | Involvement of immune responses in pulmonary arterial hypertension; lessons from rodent models |
| Q90434067 | Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension? |
| Q88734484 | Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS) |
| Q34732817 | Lung involvement in systemic sclerosis |
| Q41679546 | Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition |
| Q26766526 | Management of interstitial lung disease associated with connective tissue disease |
| Q30490484 | Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol |
| Q50051189 | Multiparametric Magnetic Resonance Imaging in the Assessment of Pulmonary Hypertension: Initial Experience of a One-Stop Study. |
| Q30463476 | N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study |
| Q37973537 | Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. |
| Q33788564 | Open label study of ambrisentan in patients with exercise pulmonary hypertension |
| Q36739951 | Outcomes in systemic sclerosis-related lung disease after lung transplantation |
| Q35093008 | Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive d |
| Q36633190 | Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study |
| Q37185564 | Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature |
| Q37157104 | Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension |
| Q45869636 | Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension |
| Q57824149 | Pulmonal arterielle Hypertonie bei Kollagenosen |
| Q92534334 | Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment |
| Q36795578 | Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis |
| Q37069668 | Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials |
| Q35002423 | Pulmonary arterial hypertension associated with systemic sclerosis |
| Q36075852 | Pulmonary arterial hypertension in connective tissue diseases. |
| Q35867030 | Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction |
| Q37053491 | Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up |
| Q35985597 | Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. |
| Q36328903 | Pulmonary hypertension in parenchymal lung disease |
| Q38075430 | Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis |
| Q47907807 | Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials |
| Q39430126 | Pulmonary hypertension secondary to hyperviscosity in a patient with rheumatoid arthritis and acquired von Willebrand disease: a case report. |
| Q33956819 | Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases |
| Q36497504 | Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort |
| Q26800639 | Pulmonary manifestations of antisynthetase syndrome |
| Q33653288 | Pulse dose steroids in severe pulmonary arterial hypertension secondary to systemic lupus erythematosus |
| Q92603571 | Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry |
| Q26773161 | Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis |
| Q30562538 | Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension |
| Q47922777 | Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis |
| Q35035897 | Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis |
| Q36864034 | SAPHIRE: Stress and Pulmonary Hypertension in Rheumatoid Evaluation-A Prevalence Study. |
| Q33965825 | Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases |
| Q56977976 | Scleroderma Lung Disease |
| Q38135045 | Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. |
| Q41356862 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. |
| Q36150934 | Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans |
| Q36508730 | Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study |
| Q92106417 | Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure |
| Q37190566 | Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats |
| Q35857181 | Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension |
| Q37345940 | Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. |
| Q40814361 | Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension |
| Q64232065 | Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast |
| Q33950086 | Systemic sclerosis-associated pulmonary arterial hypertension |
| Q38066657 | The Fra-2 transgenic mouse model of systemic sclerosis |
| Q37690888 | The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. |
| Q33702614 | The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension |
| Q35517421 | The right ventricle in scleroderma (2013 Grover Conference Series). |
| Q89558883 | The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis |
| Q46301833 | Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma |
| Q50476552 | Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. |
| Q26851767 | Treatment goals of pulmonary hypertension |
| Q34425493 | Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease |
| Q50141503 | Understanding exercise hemodynamics |
| Q34609902 | Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry |
| Q35716098 | Update on pulmonary hypertension 2009. |
| Q36810813 | Updating clinical endpoint definitions. |
| Q34782605 | Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers. |
| Q33636412 | Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia |
| Q82707675 | [Key features in the management of diffuse interstitial pulmonary disease] |
| Q88208782 | [Pulmonary hypertension in connective tissue disease] |
| Q84016583 | [Pulmonary hypertension in interstitial lung diseases: diagnostic and therapeutic approach in 2011?] |
| Q82334236 | [Scleroderma] |
Search more.